^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models

Published date:
10/12/2022
Excerpt:
The overall response rate (ORR) by investigator is 1 (4.5%) partial response (PR) and 13 (59%) stable disease (SDs), with 6 SDs for >6 months. Disease control rate (DCR) is 64%. One pt with EGFR exon 19 deletion who progressed on osimertinib has an ongoing PR for 3+ years....TP-0903 added to osimertinib in unselected resistant EGFR+ NSCLC patients showed intriguing signals of activity that deserves further investigation, the safety profile was manageable.